Dr. Andrii Buvailo is a pharmaceutical industry analyst, tech scout and writer with a focus on
artificial intelligence (AI) in drug discovery and biotech, digital transformation of pharma industry,
and the advent of novel therapeutic modalities.
Andrii’s reports touch upon disruptive biotech startups, venture capital deals, drug discovery
IPOs and platform companies. His articles were
published on Forbes,
and market research reports were referenced by some of the leading organizations (e.g. Deloitte).
Andrii is an ex-Enamine veteran, having served for the company as
Director of E-commerce and Marketing for more
than 8 years. Enamine is a global supplier of fine chemicals and compound libraries for the
pharmaceutical industry.
Before venturing into the pharmaceutical industry and media entrepreneurship, Andrii used to work as a
scientist.
He holds PhD in Physical Chemistry, and has research experience in bioinorganic and supramolecular
chemistry, thin polymer films, nanomaterials, and sensors.
Recent research reveals that blocking an inflammation-promoting protein, IL-11, can significantly extend the lifespan and improve the health of laboratory …
Artiva Biotherapeutics, a clinical-stage biotechnology company, has raised $167 million through its initial public offering (IPO). The company offered 13.9 …
Foundation models represent a new paradigm in artificial intelligence (AI), revolutionizing how machine learning models are developed and deployed. As …
We use cookies to personalise content and to analyse our traffic.
You consent to our cookies if you continue to use our website. Read more details in our
cookies policy.